Axonics (Nasdaq:AXNX) announced today that Dan Dearen, president and CFO, is retiring from his position at the neuromodulation company. Irvine, California-based Axonics tabbed Kari Keese, VP of finance and accounting, to succeed Dearen. Her appointment goes into effect on Oct. 2. “On behalf of the Axonics team and the board of directors, I want to […]
Axonics Modulation Technologies
FDA approves fourth-gen rechargeable sacral neuromod tech from Axonics
Axonics (Nasdaq:AXNX) announced today that the FDA approved its fourth-generation R20 rechargeable sacral neuromodulation system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. The approval indicates the Axonics R20 for a functional life in the body of at least 20 years. It also reduces the frequency with which a […]
Axonics receives Health Canada approval for rechargeable sacral neuromod
Axonics (Nasdaq:AXNX) announced today that Health Canada approved its fourth-generation rechargeable sacral neuromodulation (SNM) system. Irvine, California-based Axonics’ R20 neurostimulator received labeling for a functional life in the body of at least 20 years. It reduces how frequently a patient must recharge their implanted device to once every six to 10 months. The devices charge […]
Axonics stock dips after hours despite Street-beating Q3, raised guidance
Axonics (Nasdaq:AXNX) shares took a hit after hours despite third-quarter results that bettered the consensus forecast. Shares of AXNX dipped 7% to $68 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. The Irvine, California-based sacral neuromodulation (SNM) […]
10 big earnings stories from the last quarter: How are medtech stocks doing now?
Economic uncertainty appears to have produced a wide variety of medtech earnings stories during the most recent round of quarterly results. Some medical device companies received massive boosts from their quarterly performance, while others saw their stocks sink amid missed projections and other various issues. The phrase “macroeconomic headwinds” was a common phrase. Medtech faces […]
Axonics expands IP portfolio with new patents
Axonics (Nasdaq:AXNX) announced today that it has been granted eight patents and allowed a further four applications in the past 12 months. Irvine, California-based Axonics eight granted patents and four applications to the U.S. Patent and Trademark Office relate to its portfolio of sacral neuromodulation (SNM) technology. According to a news release, the patents represent […]
Axonics expects 40% revenue growth this year
Axonics (Nasdaq:AXNX) shares are on the rise today on second-quarter results that came in ahead of the consensus forecast amid a successful TV advertising campaign. The Irvine, California–based sacral neuromodulation technology developer posted losses of $34.1 million, or 47¢ per share, on sales of $69 million for the three months ended June 30, 2022, for […]
Axonics files FDA PMA supplement for 4th-gen rechargeable neurostimulator
Axonics (Nasdaq:AXNX) announced that it filed a premarket approval (PMA) supplement with the FDA for its next-generation neurostimulator. Irvine, California–based Axonics designed its fourth-generation rechargeable sacral neuromodulation implantable neurostimulator (INS) to reduce the frequency with which a patient needs to recharge their implanted device to just once every six months for one hour. The current […]
Axonics raises 2022 sales guidance on Street-beating Q1
Axonics Modulation Technologies (Nasdaq:AXNX) reported first-quarter financial results that topped analysts’ consensus forecast. The Irvine, California–based sacral neuromodulation technology developer posted losses of $22.7 million, or 50¢ per share, on sales of $48.4 million for the three months ended March 31, 2022, for a slight bottom-line loss of just over $150,000 year-over-year on sales growth […]
Axonics launches F15 recharge-free sacral neuromodulation system
Axonics (Nasdaq:AXNX) announced today that it launched its F15 recharge-free sacral neuromodulation (SNM) system in the U.S. Irvine, California-based Axonics received FDA approval for the F15 SNM system in March. The company designed the newly developed F15 recharge-free SNM system to feature a functional life span of over 15 years at typical stimulation parameters, with […]
FDA clears Axonics’ recharge-free sacral neuromodulation system
Axonics Modulation Technologies (Nasdaq:AXNX) announced today that it received FDA approval for its new implantable neurostimulator. Irvine, California–based Axonics designed the Axonics F15 recharge-free sacral-neuromodulation (SNM) system with a functional life span of over 15 years at typical stimulation parameters and more than 2 decades at lower-energy settings. The system’s size totals 10 cubic centimeters, […]
